Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
|---|---|---|---|---|---|
| IFB-H5253 | Human | Human IFN-alpha 2b Protein, Fc Tag (MALS verified) |  |
|
Human IFN-alpha 2b (K46R), Fc Tag (Cat. No. IFB-H5253) immobilized on CM5 Chip can bind Human IFNAR2, His Tag (Cat. No. IF2-H5224) with an affinity constant of 0.257 μM as determined in SPR assay (Biacore T200) (Routinely tested).
The purity of Human IFN-alpha 2b, Fc Tag (Cat. No. IFB-H5253) is more than 90% and the molecular weight of this protein is around 95-105 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Nadofaragene firadenovec | SCH-721015 | Approved | Schering - Plough Sa, Fkd Therapies | Adstiladrin | United States | Urinary Bladder Neoplasms | Ferring Pharmaceuticals A/S | 2022-12-16 | Mesothelioma; Urinary Bladder Neoplasms | Details |
| Nadofaragene firadenovec | SCH-721015 | Approved | Schering - Plough Sa, Fkd Therapies | Adstiladrin | United States | Urinary Bladder Neoplasms | Ferring Pharmaceuticals A/S | 2022-12-16 | Mesothelioma; Urinary Bladder Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science) | Phase 2 Clinical | Genenta Science Srl | Glioblastoma; Multiple Myeloma | Details | |
| CX-801 | CX-801 | Phase 1 Clinical | Cytomx Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma | Details |
| Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science) | Phase 2 Clinical | Genenta Science Srl | Glioblastoma; Multiple Myeloma | Details | |
| CX-801 | CX-801 | Phase 1 Clinical | Cytomx Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma | Details |
This web search service is supported by Google Inc.
A-Z
